Home
|
Inbox
|
Search
|
View Abstract
Yamagata University Hospital's Criteria for Discriminating Patients Overlapping Asthma Among COPD Patients
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A5043 - Yamagata University Hospital's Criteria for Discriminating Patients Overlapping Asthma Among COPD Patients
Author Block: H. Machida; Yamagata University school of Medicine, Yamagata, Japan.
[Background] Asthma-COPD overlap (ACO) is a significant clinical phenotype of COPD. Inhaled corticosteroid (ICS) is recommended for its treatment. However, to date, there is no universally accepted definition of ACO. We aimed to establish criteria for discriminating patients overlapping asthma among COPD patients. [Methods]We set the items of the criteria as followed: 1) presence of asthmatic symptoms; 2) previous physician’s diagnosis of asthma; 3) a history of atopic dermatitis or allergic rhinitis; 4) bronchodilator reversibility; 5) elevated peripheral eosinophils; 6) increase of fractional exhaled nitric oxide. We defined ACO when the patients meet 1), or 2) and at least one of 3)-6). We enrolled 148 patients with COPD, and examined whether they met our diagnostic criteria. We also investigated the use of ICS at the time before diagnosis using this criteria. [Results] Forty-three patients (29.1%) were matched with our criteria for diagnosis of ACO, and there were no significant differences in age and sex between subjects with ACO and non-ACO. In patients with ACO, increased number of peripheral eosinophils and higher COPD assessment test (CAT) score were observed, and CT-evaluated low attenuation area in lungs were significantly less than those of non-ACO. In patients with ACO, the use of ICS was significantly more common than non-ACO. [Conclusion] Our criteria were matched with the prevalence of ACO that who were previously reported. Our criteria may be a useful for discriminating the subjects overlapping asthma among patients with COPD.
Author Block: H. Machida; Yamagata University school of Medicine, Yamagata, Japan.
[Background] Asthma-COPD overlap (ACO) is a significant clinical phenotype of COPD. Inhaled corticosteroid (ICS) is recommended for its treatment. However, to date, there is no universally accepted definition of ACO. We aimed to establish criteria for discriminating patients overlapping asthma among COPD patients. [Methods]We set the items of the criteria as followed: 1) presence of asthmatic symptoms; 2) previous physician’s diagnosis of asthma; 3) a history of atopic dermatitis or allergic rhinitis; 4) bronchodilator reversibility; 5) elevated peripheral eosinophils; 6) increase of fractional exhaled nitric oxide. We defined ACO when the patients meet 1), or 2) and at least one of 3)-6). We enrolled 148 patients with COPD, and examined whether they met our diagnostic criteria. We also investigated the use of ICS at the time before diagnosis using this criteria. [Results] Forty-three patients (29.1%) were matched with our criteria for diagnosis of ACO, and there were no significant differences in age and sex between subjects with ACO and non-ACO. In patients with ACO, increased number of peripheral eosinophils and higher COPD assessment test (CAT) score were observed, and CT-evaluated low attenuation area in lungs were significantly less than those of non-ACO. In patients with ACO, the use of ICS was significantly more common than non-ACO. [Conclusion] Our criteria were matched with the prevalence of ACO that who were previously reported. Our criteria may be a useful for discriminating the subjects overlapping asthma among patients with COPD.
|
Home
|
Inbox
|
Search
|